Vor Biopharma Inc. (VOR) has a MoatMap StockRank of 28/100 based on Quality (30/100), Value (43/100), and Momentum (41/100) factor scores. The current signal is SELL. Vor Biopharma is a clinical-stage cell therapy developer. It is pre-revenue, highly speculative, and lacks the established commercial moat and predictable cash flows required for our portfolio.
Vor Biopharma is a clinical-stage biotechnology company developing engineered hematopoietic stem cell (eHSC) therapies for blood cancers. Its proprietary eHSC platform aims to enable targeted therapies post-transplant, addressing a significant unmet medical need. This focus on immuno-oncology and cell therapy offers a potential competitive advantage in a rapidly evolving treatment landscape.
| Price | $13.28 |
| Market Cap | $813M |
| P/E (Forward) | -3.83 |
| Price/Book | -3.37 |
| Return on Invested Capital | -84.7% |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-196M |
Vor Biopharma Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).